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Abstract
Background Deficiency of 4-aminobutyrate aminotransfer-
ase (GABA-T) is a rare disorder of GABA catabolism, with
only a single sibship reported. We report on a third case, a
Japanese female infant with severe psychomotor retardation
and recurrent episodic lethargy with intractable seizures,
with the diagnosis facilitated by proton magnetic resonance
(MR) spectroscopy (
1H-MRS).
Methods Neuroimaging was performed at the first episode
of lethargy. For
1H-MRS, locations were placed in the
semioval center and the basal ganglia. Quantification of
metabolite concentrations were derived using the LCModel.
We confirmed the diagnosis subsequently by enzyme and
molecular studies, which involved direct DNA sequence
analysis and the development of a novel multiplex ligation-
dependent probe amplification test.
Results
1H-MRS analysis revealed an elevated GABA
concentration in the basal ganglia (2.9 mmol/l). Based on
the results of quantitative
1H-MRS and clinical findings,
GABA-T deficiency was suspected and confirmed in
cultured lymphoblasts. Molecular studies of the GABA-T
gene revealed compound heterozygosity for a deletion of
one exon and a missense mutation, 275G>A, which was not
detected in 210 control chromosomes.
Conclusions Our results suggest that excessive prenatal
GABA exposure in the central nervous system (CNS) was
responsible for the clinical manifestations of GABA
transaminase deficiency. Our findings suggest the dual
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DOI 10.1007/s10545-009-9022-9nature of GABA as an excitatory molecule early in life,
followed by a functional switch to an inhibitory species
later in development. Furthermore, quantitative
1H-MRS
appears to be a useful, noninvasive tool for detecting inborn
errors of GABA metabolism in the CNS.
Abbreviations
GABA-T Gamma aminobutyric acid transaminase
1H-MRS Proton magnetic resonance spectroscopy
CNS Central nervous system







Disorders of gamma aminobutyric acid (GABA) metabolism
are rare and manifest prominent neurological sequelae; 4-
aminobutyrate aminotransferase (γ-aminobutyrate: GABA
transaminase, or GABA-T; OMIM 137150) deficiency is
characterized by severe psychomotor retardation, hypotonia,
hyperreflexia, seizures, high-pitched cry, and growth accel-
eration, associated with early infantile death in two siblings
(one family) (Jaeken et al 1984; Jakobs et al 1993). Succinic
semialdehyde dehydrogenase (SSADH) deficiency [or 4-
hydroxybutyric (GHB) aciduria] is the most prevalent of the
GABA degradation disorders and one in which pharmaco-
logically active GHB, as well as GABA, accumulate in
patient body fluids (Jakobs et al 1993; Pearl et al 2007).
Homocarnosinosis (homocarnosine is the GABA:L-histidine
Fig. 1 Initial computed tomography (CT) and magnetic resonance
imaging (MRI) findings at 8 months. Baseline CT (a), T1-weighted
(b), T2-weighted (c), diffusion-weighted (d) axial MRI images, and
apparent diffusion coefficients (ADC) map (e) at the level of the basal
ganglia, and diffusion-weighted images (DWI) of the semioval center
(f). CT (a) shows no particular abnormality, whereas T1-weighted (b)
and T2-weighted (c) images suggest delayed myelination. Subcortical
high white-matter signal on the T1-weighted image was not observed,
and low signal on the T2-weighted image was limited to the posterior
portion of the internal capsules and splenium of the corpus callosum.
DWI (d, f) shows widespread high signals in the internal and external
capsules and many parts of the subcortical white matter, with
restricted diffusion (e)
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allelic form of carnosinase deficiency(Pearl et al 2007).
Considering the inhibitory nature of GABA activity in the
central nervous system (CNS), the paradoxical neurological
phenomenon associated with seizures in cases of GABA
excess is of interest. In this study, we detected elevated
GABA in a patient by proton magnetic resonance spectros-
copy (
1H-MRS) using the LCModel to quantify the spectra
automatically. This method has potential application to
neurological disorders such as GABA-T deficiency.
Case report
The patient was a Japanese female infant, born full term
with normal delivery. She was the second child of healthy
parents. There was no consanguinity or family history of
neurological disorders. A 6-year-old sister was normal.
Early infancy was unremarkable. At 7 months, she was
evaluated for psychomotor retardation, hypotonia, bilateral
intermittent esotropia, hyperreflexia, and positive Babinski
reflex. There was no dysmorphy. At age 8 months, she was
admitted with decreased consciousness 48 h after an acute
febrile illness. Respiratory distress developed that required
mechanical ventilation. Steroid pulse therapy was initiated
for a suspected acute encephalopathy of unknown etiology.
Segmental myoclonic jerks occurred and were difficult to
control, but consciousness returned. Electroencephalogra-
phy (EEG) revealed diffuse slow spike and wave discharges
with 1- to 2-s periods of suppression. Phenobarbital,
clonazepam, valproate, and midazolam could not complete-
ly control seizures. Limb motor conduction velocities were
Fig. 2 LCModel outputs of in vivo proton magnetic resonance (MR)
spectra from the basal ganglia (volume, 10–17.5 ml; TE/TR, 20–30/
5000 ms; number of excitations 6). Bold lines indicate LCModel
fitting, and thin lines indicate the original spectra. Patient with gamma
aminobutyric acid transaminase (GABA-T) deficiency (8 months) (a),
a control individual (7 months) (b). Bold lines in the upper row are the
fitting curves of total spectra including all metabolites, and those in
the lower row are fitting curves for GABA. The estimated absolute
concentrations of GABA in patient and control are 2.9 and 0.8 mmol/l,
respectively. Normal GABA spectrum exhibits a quintet (
3CH2)a t
1.89 ppm, a triplet (
4CH2) at 2.28 ppm, and a multiplet resembling a
triplet (
2CH2) at 3.01 ppm(Govindaraju et al 2000)
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accelerated height in late infancy [+2.5–3.0 standard
deviation (SD)], with normal head circumference and
decreased weight gain. At 8 months, her height was
76 cm (+3.0 SD), weight 6745 g (−1.7 SD), and head
circumference 44 cm (−0.4 SD). Nasogastric tube feeding
was started due to recurrent aspiration pneumonia. At
11 months, domiciliary oxygen was introduced because of
chronic respiratory failure. At the age of 28 months, her
height was 96 cm (+2.9 SD), weight 10.3 kg (−1.1 SD), and
head circumference 46.5 cm (−0.7 SD). Febrile illness was
consistently associated with neurological deterioration, and
the patient progressed to opisthotonic posturing with
generalized dystonia and segmental myoclonic jerks, which
never resolved while awake.
Methods and results
Laboratory data
Routine laboratory tests were normal. Amino acid analysis
showed elevated free GABA in the serum and cerebral
spinal fluid (CSF) at 9 months of age (2.1 μmol/l and
1.26 μmol/l, respectively; normal range serum 0.12–0.50,
CSF 0.04–0.12) (Jaeken et al 1984). Serum growth
hormone was elevated (8.84 ng/ml; normal range 0.28–
1.64). Insulin-like growth factor levels were relatively low
(54 ng/ml; normal range 37–229). An absence of GHB in
urine organic acid analysis precluded SSADH deficiency as
a cause of increased GABA. β-alanine and homocarnosine
were not detectable on the chromatogram, and their
quantitative analyses were not performed.
Radiological findings
Bone age was 1 year 8 months at the age of 1 year 10
months (TW2 method). Initial brain computed tomography
(CT) was unremarkable (Fig. 1a), and brain magnetic
resonance imaging (MRI) (1.5 T) suggested mild delay in
myelination (Fig. 1b, c) without structural anomalies.
Diffusion weighted images (DWI) revealed high signal
intensity in the internal and external capsules and much of
the subcortical white matter, with restricted apparent
diffusion coefficiency (Fig. 1d–f). For quantitative
1H-MRS
(age 8 months), locations were placed in the white matter
(semioval center) and the basal ganglia (10 ml).
1H-MR
spectra were obtained using the stimulated-echo acquisition
mode (STEAM) sequence (Frahm et al 1987)( T E / T R =
20/5,000 ms). To quantify the spectra, the LCModel
(Provencher 1993) was used. The LCModel facilitates
metabolite separation based upon differing linear combina-
tions of spectra of individual metabolites and estimates the
concentration of each metabolite concentration by comparing
the proton concentration of water in identical voxels. The
GABA concentration in the basal ganglia (Fig. 2)w a s
Table 1 Clinical, enzymatic, and molecular characteristics of gamma aminobutyric acid transaminase (GABA-T)-deficient patients
Sign/symptom Patient 1 Patient 2 (sib of patient 1) This report
Intractable seizures + + +
Psychomotor retardation + + +
Hypotonia + + +
High-pitched cry + + –
Hyperreflexia + + +
Lethargy + + +
Acceleration of height growth + + +
Age of death 25 months 12 months Alive at 28 months
EEG/MRI/CT abnormalities + + +
GABA-T (liver)
a 70 (310–690) ––
GABA-T (white cells)
b 1.2 (20–58) – 2 (23–64)
Genotype
c c.[659G>A (+) 1433T>C]
d – c.[275G>A ]+[199–?_316+?]
e
Deduced effect p.[Arg220Lys (+) Leu478Pro] – p.[Arg92Gln ]+[?]
EEG electroencephalograph, MRI magnetic resonance imaging, CT computed tomography, + present; – absent or not determined.
aProtein pmol/h/mg (control range in parentheses).
bProtein pmol/min/mg (control range in parentheses).
c Reference sequence NM_000663.3;
missense mutations are considered to be pathogenic, as they were not encountered in 210 control chromosomes and involve highly conserved
amino acids among GABA-T species.
dFollowing the original publication (Jaeken et al 1984), we identified the second mutation (c.1433T>C) in
the first described patient, confirming GABA-T deficiency at the DNA level.
eIn our patient, a presumed homozygous mutation was detected by
direct sequence analysis; however, this was in contrast to the findings in DNA of the mother. The heterozygous mutation could not be detected in
DNA of the father, therefore, a specific multiplex probe amplification test was developed. This showed the presence of a heterozygous exon
deletion in DNA of the patient confirming compound heterozygosity
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n=9), but in the semioval center, GABA elevation was slight
(0.8 mmol/l; normal 0.5 mmol/l±0.2, n=9). Glutamine/
glutamate complex (Glx) concentration was also slightly
elevated in the semioval center (11.3 mmol/l in the basal
ganglia, 8.3 mmol/l in the semioval center; normal 10.1 mmol/l
±1.5,6.6mmol/l±1.0, n=9, respectively). Follow-up
1H-MRS
analysis (at 9 months of age) revealed a more pronounced
GABA elevation both in the basal ganglia and in the semioval
center (5.9 mmol/l and 2.9 mmol/l, respectively). Based on
these data and the results of quantitative
1H-MRS, we
suspected GABA-T deficiency, which was confirmed by
enzyme and molecular studies in cultured lymphoblasts
(Schor et al 2001)( T a b l e1).
Discussion
This report is on the third patient (second family) with
GABA-T deficiency and the first patient in whom
1H-MRS
was performed. All three patients showed severe, nonspe-
cific neurological manifestations, including psychomotor
retardation, epilepsy, hypotonia, and hyperreflexia (Table 1),
but our patient appeared less severely affected than the
reported patients. All three also showed growth acceleration
associated with increased serum growth hormone levels.
The underlying pathophysiology in GABA-T deficiency
remains to be elucidated, and there is no animal model
available. Evidence from animal studies indicates a neuro-
toxic role for supraphysiological GABA levels. For
example, inhibition of GABA-T by the irreversible inhib-
itor, vigabatrin, induces intramyelinic edema in dogs via
GABA elevation (Peyster et al 1995). Both GABA-T and
SSADH deficiencies manifest seizures, which is paradox-
ical, as activation of the GABAergic system is predicted to
be anticonvulsive. Nonetheless, it is important to remember
that GABA is excitatory in the developing rodent brain and
remains so for the first 1–2 weeks of life. Along these lines,
the switch of GABA from a depolarizing to a hyper-
polarizing response is critically important in the rodent
substantia nigra pars reticulata (SNR), which has one of the
highest concentrations of GABAergic neurons in the CNS
(Iadarola and Gale 1982). In the murine model of SSADH
deficiency, Jansen and coworkers (2008) demonstrated a
significant increase in GABA in E10 embryos, which may
predispose these animals to a hyperexcitatory state during
development. This result, along with GABA(A) and GABA
(B) receptor anomalies detected in developing SSADH-
deficient mice, may reduce the seizure threshold in SSADH
deficiency (Buzzi et al 2006;W ue ta l2006). Both
disorders occupy juxtaposed positions in GABA degrada-
tion, and accordingly we speculate that the pathophysio-
logical mechanisms observed in SSADH deficiency may be
likely to be caused by high GABA levels, as observed in
GABA-T deficiency. Neuropathology of the two index
cases revealed spongy leukodystrophy, which may corre-
spond to the white matter lesions seen on DWI in our
patient. This observation may reflect changes in water
motion in the axonal direction and/or axonal swelling
associated with cortical neuronal damage.
Whereas
1H-MRS estimates in vivo neurotransmitter
concentrations (Provencher 1993), quantifying GABA in
nonpathological states is difficult due to interference by
much larger peaks of the glutamine–glutamate complex,
creatine, and large peaks of N-acetylaspartic acid (Novotny
et al. 2003). However, utilizing the LCModel facilitates
separationofevenlow-concentrationspecies (suchasGABA)
from other major compounds. Screening of the metabolite
concentration by
1H-MRS may readily reveal the patho-
logical state, however, as in our patient. Moreover, the
addition of a short exposure to
1H-MRS may be acceptable,
even in infants and children. Increased intracranial
GABA detected by
1H-MRS has been reported in SSADH
deficiency (Ethofer et al 2004), but additional GABA-T-
deficient patients require identification in order to determine
how the concentrations of intracranial GABA compare to
those in the same regions of SSADH-deficient patients.
In summary, GABA transaminase deficiency represents
a human model of endogenous GABA elevation, which
likely occurs during critical periods of human CNS
development. This disorder may offer valuable insights
into the role of the GABAergic system in human brain
development. Our studies further suggest that quantitative
1H-MRS may be clinically applicable to the inborn errors
of GABA metabolism.
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